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INTRODUCTION
Head and neck cancers are the seventh most common 
cancer globally. Approximately 50% of the patients 
die within 5 years. Current diagnostic methods include 
clinical assessment, imaging and tissue biopsy [1]. When 
metastases are clinically evident, treatment is palliative 
in nature only. There are currently no methods to predict 
which patients with a higher disease burden will develop 
metastases. The ability to do so would potentially lend itself 
to treatment escalation at diagnosis. Circulating tumour 
cells (CTCs) found in the lymphovasculature are thought 
to have the propensity to metastasize at distant sites. CTCs 
are extremely rare events (typically a few CTCs per 106–9 
blood cells), therefore very sensitive methodologies are 
required to isolate these cells [2]. Enrichment strategies 
aim to increase the CTC concentration from blood by 
several log units for easier detection by downstream 
methodologies. Biological approaches for CTC enrichment 
can include positive selection using anti-epithelial marker 
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ABSTRACT
Minimally invasive techniques are required for the identification of head and 
neck cancer (HNC) patients who are at an increased risk of metastasis, or are not 
responding to therapy. An approach utilised in other solid cancers is the identification 
and enumeration of circulating tumour cells (CTCs) in the peripheral blood of 
patients. Low numbers of CTCs has been a limiting factor in the HNC field to date. 
Here we present a methodology to expand HNC patient derived CTCs ex-vivo. As a 
proof of principle study, 25 advanced stage HNC patient bloods were enriched for 
circulating tumour cells through negative selection and cultured in 2D and 3D culture 
environments under hypoxic conditions (2% O2, 5% CO2). CTCs were detected in 
14/25 (56%) of patients (ranging from 1–15 CTCs/5 mL blood). Short term CTC 
cultures were successfully generated in 7/25 advanced stage HNC patients (5/7 of 
these cultures were from HPV+ patients). Blood samples from which CTC culture 
was successful had higher CTC counts (p = 0.0002), and were predominantly from 
HPV+ patients (p = 0.007). This is, to our knowledge, the first pilot study to culture 
HNC CTCs ex-vivo. Further studies are warranted to determine the use of short term 
expansion in HNC and the role of HPV in promoting culture success.
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antibodies (EpCAM), anti-mesenchymal marker antibodies 
(N-cadherin) or negative selection using antibodies against 
CD45 to deplete leukocytes [3]. Moreover, the physical 
properties of CTCs can be employed for cell separation 
(size, density, electric charge and deformability [3–5]. 
There has been a shift in CTC enrichment and 
detection technologies away from positive selection 
marker based platforms such as the FDA-approved 
CellSearch®, to label free methodologies [6]. CellSearch® 
CTC enumeration has shown clinical relevance in 
EpCAM+ CTCs across multiple tumour types, however, 
to date, none of the other technologies have been clinically 
validated [7]. Currently, the CIRCUTEC clinical trial is 
investigating CTCs as an early predictive marker or 
response to a first line anti-EGFR therapy (Cetuximab) 
in metastatic head and neck squamous cell carcinoma. 
During enumeration by CellSearch®, cells are fixed before 
isolation, disallowing propagation. Technologies that 
are able to keep CTCs viable are desirable in the field, 
especially non-marker based assays that utilise negative 
selection techniques capable of capturing a larger CTC 
population from the patient’s circulation.
One way to enable the molecular and functional 
analysis of the few CTCs that are present in circulation 
is to expand the CTCs ex-vivo. This has shown promise 
in breast, prostate and lung cancer where short term CTC 
culture has been performed [4, 8, 9]. Until recently, CTC 
expansion ex-vivo was the bottleneck in the field. The need 
for new isolation technologies that preserve the CTCs 
integrity in order to perform functional analysis has been 
a recent emphasis [9, 10]. Viable CTCs grown in culture 
can potentially be used for therapeutic screening and used 
to guide patient therapy. Studies have shown in small-cell 
lung cancer that CTC-derived explants mirror the donor 
patient’s response to chemotherapeutics [11]. Through 
the creation of CTC cell lines and analysis, personalized 
drug screening can be performed revealing the mutational 
landscape and identifying new therapeutic targets [12]. 
Recently, by use of a novel 3D organoid system, the 
long term culture of prostate cancer from patient biopsies 
and CTCs using a defined media was reported [8]. In this 
pilot study, we aimed to use the defined media, to culture 
HNC patient derived CTCs in 2D and 3D formats. 
RESULTS 
Patient characteristics
A total of 25 HNC patients were recruited for this 
study and for all samples CTC cultures attempted. The 
median age was 60 years (range 49–85); men (n = 20), 
women (n = 5). All the patients were at advanced clinical 
stage ranging from T3N0 to T4aN2b. Distant metastasis 
was assessed by an MDT clinic using advanced imaging 
platforms. HNC patients (100%) were found to be 
radiographically M0 and 28% were HPV-positive. The 
clinical details of the short term culture positive samples 
is presented on Table 1.
RosetteSepTM
The RosetteSepTM protocol was used to enrich 
for CTCs in all 25 HNC patient samples. CTCs were 
detectable 14/25 (56%) of the samples (Figure 1). It 
should be noted that only half of the enriched volume was 
cytospun onto a glass slide to be stained and the other half 
Figure 1: Immunofluorescent staining of CTCs from RosetteSep™ enrichred head and neck cancer patient blood 
samples (Row 1: Pt #10, Row 2: Pt #17), stained with an antibody cocktail (Cellsearch®: anti-Cytokeratin 8/18/19, 
DAPI, anti-CD45) and anti-EGFR. Cells found to be CD45 negative.
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was put into culture. This ensured a CTC count at time 
point zero from the equivalent of 5 mL of whole blood. 
CTC ex-vivo expansion
Short term cultures were successful propagated 
in 7/25 samples (Table 1 and Figure 2). All patients 
presenting with successful cultures had CTCs detectable at 
time point zero by immunofluorescent staining (Figure 1). 
5/7 of the expandable samples had patient primary HNCs 
originating from the oropharyngeal region. Blood samples 
from which CTC culture was successful had higher CTC 
counts (Figure 3: p = 0.0002; Mann-Whitney test), as were 
those from HPV+ patients (Table 2: p = 0.007; Fisher’s 
exact test). In patients 1, 6 and 7 (< 5CTCs/5 ml blood), a 
low CTC cell confluency was reached in 14 days, which 
continued till Day 21 (Supplementary Figure S2). In 
patients 9 and 10 (> 7CTC/5 ml blood), CTCs were highly 
confluent on day 14, proliferative up to day 35 and day 
50 in 2D respectively, and 2 weeks longer in the Happy 
Cell® (Supplementary Figure S3). In patient 14 (4 CTCs/5 
ml blood), 40% confluency was reached at day 14 and 
remained proliferative till day 28. In patient 17 (9 CTCs/5 
ml blood), 70% confluency was reached on day 14, 
remained proliferative till day 25 in 2D and day 40 in 3D. 
In all patients with a CTC count of more than 5CTCs/5 mL 
blood, the cell confluency on day 14 was much higher each 
time and remained viable for longer than when less than 
5 CTCs were found. In cultured spheroids, a necrotic core 
was found in most cases (Figure 4). As a control, 4 normal 
healthy volunteers were screened and no CTC-events were 
observed in 2D/3D culture (Supplementary Figure S1).
DISCUSSION 
CTCs were detected in 14/25 of the advanced stage 
HNC patients ranging from 1–15 CTCs/5 mL patient 
blood. In the 10 mL blood draw, the actual CTC count 
in these late stage patients could be approximated to be 
higher. The number of CTCs was determined at time point 
zero to establish a CTC count prior to culture. By use of 
a label-free technology, we are able to show that higher 
CTC counts are found than previously reported for CTC 
studies in HNC utilising the EpCAM biased Cellsearch® 
system [1, 13, 14]. However, the discovery and validation 
of new CTC markers remains in its infancy [3, 15]. 
The short term cultures in this study were from 
advanced stage HNC patients, the bulk of which 
were HPV positive (71.4%) and originating from the 
oropharynx. HPV oncogenes E6/E7 have been shown to 
inactivate tumour suppressor genes p53 and Rb, inducing 
a replicative senescent state for the immortalization 
of primary cells. In the first 3 patients (#1,6–7), CTCs 
were successfully cultured up to 21 days under low cell 
confluency (10–20%). There were sporadic areas of 
growth in 2D with high cell populations in those select 
areas reflecting cells which may have proliferated more 
rapidly. This highlighted that a high initial CTC density 
was required to promote ex-vivo culture [9]. In patients 
(#9,10,17), with higher CTC counts at time zero, much 
higher confluences were reached at day 14 (60–70%), 
reflecting the higher initial CTC numbers. These patient 
CTCs were cultured in 3D, and in all 3 cases remained 
more viable than in 2D. A high CTC count has been a 
requirement for long term patient cultures and the creation 
Table 1: Clinical details, CTC counts and culture notes of short term culture positive samples
Patient #
Tumour 
Location Staging HPV status
CTC count 
/5ml blood
Culturability
1 Oropharynx T4aN2a + 4 20% confluency on day 14Proliferative up to day 21 in 2D
6 Oropharynx T4N0 + 3 10% Confluency on day 14Proliferative up to day 21 in 2D
7 Nasopharynx T4N0 + 3 20% confluency on day 14Proliferative up to day 21 in 2D
9 Oropharynx T4aN2b – 7
60% confluency on day 14
Proliferative up to day 25 in 2D and 50 
days in 3D
10 Oropharynx T3N1aM0 + 15
70% confluency on day 14
Proliferative up to day 50 in 2D and 63 
days in 3D
14 Oropharynx T4aN2b + 4 40% confluency on day 14Proliferative up to day 28 in 2D
17 Supraglottis T3N0 –  9
70% confluency on day 14
Proliferative up to day 25 in 2D and
Day 40 in 3D
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Figure 2: Short term CTC cultures in 2D (MSK media, day 7, 2% O
2
). Row (A) 96 well standard microplate, Row (B) Corning® 
Spheroid Microplates (ThermoScientific, USA). (C) In well staining of proliferating cells in culture at day 7. Immunofluorescent staining 
with combination antibody (Cellsearch™: Cytokeratin 8,18–19, DAPI, CD45) and EGFR. These cells were found to be CD45 negative (not 
shown). Arrows represent single/clusters of CTCs.
Table 2: Correlation between HPV status and short term culture success
Culture negative Culture positive
HPV-negative 16 2
HPV-positive 2 5
P = 0.007; Fisher’s exact test.
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Figure 3: CTC count vs short term culture success. P = 0.0002; Mann-Whitney test. Error bars represent standard deviation.
Figure 4: (1A) Short term CTC cultures in 3D (MSK media, day 14, 2% O2). (2A) Cell cluster under bright field. (2B) CellSearch® 
DAPI immunofluorescent staining (2C) CellSearch pan-cytokeratin immunofluorescent staining. These cells were found to be CD45 
negative (3A) Spheroid under bright field (3B) Live/dead immunofluorescent stain (FDA; green) (PI; red) showing a necrotic core.
Oncotarget6www.impactjournals.com/oncotarget
of stable cell lines reflecting the high CTC density required 
for ex-vivo propagation [8, 9, 16, 17]. 2D and 3D culture 
formats tended to proliferate better in standard 96-well 
microplates and spheroid microplates respectively.
This study demonstrates that HNC patient derived 
CTCs can be expanded ex-vivo. The importance of ex- vivo 
CTC work has been demonstrated in numerous other 
cancer models [16–19]. Further studies are warranted in 
the HNC field that create cell lines which can be used to 
test new therapeutic approaches. More importantly, novel 
immunotherapies are being developed against proteins 
that can block the immune response of T-cells such as PD-
L1 [19], which has shown to be in frequently expressed 
in breast cancer [10]. For the establishment of CTC cell 
lines in HNC patients, isolation of higher numbers of 
CTCs is warranted. This is currently possible through 
leukopheresis where litres of blood are filtered for CTCs 
rather than the conventional 10 mL [20]. Alternatively 
identifying HNC patients with a heavy burden of disease 
and known metastatic disease may provide higher CTC 
counts for enrichment and culture. However, the clinical 
importance is in extending this technology to early stage 
patients. Low-risk patients presenting with CTCs could 
be recruited into clinical trials to determine the benefit 
of adjuvant therapy as opposed to waiting for overt 
metastasis to develop [21].
MATERIALS AND METHODS
Patient cohort
Ethics approval was obtained by the Metro South 
Health Service District Research Ethics committee 
in accordance with the National Health and Medical 
Research Council’s guidelines (HREC/12/QPAH/381) 
to collect blood from the Princess Alexandra Hospital 
(PAH). This study has UQ ethics approval (2009000779) 
and QUT ethics approval (1400000617). After written 
informed consent was obtained from the participants, 10 
mL blood samples were obtained from patients presenting 
with HNC. The clinicopathological patient findings are 
presented in Table 3. 
Preparation of blood samples and CTC 
enrichment
Whole blood (10 mL) was collected in heparin 
tubes (BD-Plymouth, UK) and incubated with 
RosetteSepTM Human CD45 depletion cocktail (Stemcell 
Technologies™, Vancouver, Canada) at 50 µl/mL of 
whole blood for 20 minutes at room temperature. Cellular 
separation was performed in SepMate™-50 mL tubes 
containing a density gradient medium - Lymphoprep™ 
(Stemcell Technologies™, Vancouver, Canada). Half of 
the cell suspension was spun onto glass slides using the 
Cytospin™ 4 Cytocentrifuge (ThermoScientific, USA), air 
dried and fixed with 4% PFA. The presence of CTCs was 
verified by immunofluorescent staining and analysed using 
an Olympus IX3 Inverted microscope. The other half of 
the enriched cellular suspension was cultured in 2D and 
3D media under hypoxic conditions.
CTC parameters
CTCs were visualized using immunofluorescence 
post RosetteSepTM enrichment and in culture using 
the Cellsearch® (Janssen Diagnostics) antibody stain 
(Cytokeratin 8, 18, 19, CD45 and DAPI). Cells were 
classified as CTCs if (i) Morphologically larger than the 
background cells with intact nuclei (ii) High nucleus-
cytoplasmic ratio (iii) pan-cytokeratin positive (iv) 
CD45 negative. Further characterization was done 
using (v) EGFR immunostaining (AY13) (Biolegend, 
CA, USA). and DNA FISH (Supplementary Figure S4) 
Stained slides were manually examined by two trained 
users and questionable events evaluated until consensus 
was reached. The results were reported as number of 
CTCs/5 mL whole blood.
Ex-vivo expansion of CTCs
Isolated CTCs were cultured in the following 
formats: 96 well standard microplates, 96F non adherent 
microplates, spheroid microplates (Thermo Scientific, 
USA) and specialized microwell formats with a culture 
medium containing Advanced DMEM/F12 with the 
following additives: 50 ng/mL EGF (Sigma), 5% 
v/v R-spondin 1, 10% v/v Noggin, 10 ng/mL FGF10 
(Peprotech), 1 ng/ml FGF2 (Peprotech), 10 nM 
Nicotinamide (Acros), 0.5 µM A83–01 (Tocris), 10 µM 
SB202190 (Sigma Aldrich), 10 µM Y-27632 (Selleck 
Chemical), 1X B27 Additive (Invitrogen), 1.25 mM 
N-Acetyl-L-cysteine (Sigma-Aldrich), 2 nM Glutamax 
(Invitrogen), 10 mM HEPES (Sigma Aldrich), 1:100 v/v 
Primocin (Invivogen). For 3D ex-vivo expansion, Happy 
Cell® (Biocroi Ltd, Dublin, Ireland) hydrogel was used in 
combination with the above mentioned cocktail to provide 
the environment for the CTCs. To perform spheroid 
staining, an inactivation buffer was added to the culture 
for 1 hour at 37oC to collapse the Happy Cell® matrix. 
Cultures were incubated under hypoxic conditions (2% O2, 
5% CO2) and imaged weekly starting on day 7.
Live/dead staining
Spheroids found in cultures were simultaneously 
stained with two fluorescent dyes to distinguish between live 
and dead cells as per manufacturer’s instruction. Fluorescein 
diacetate (FDA) (Thermoscientific, USA) stains live cells 
green by converting into green fluorescent metabolite 
fluorescein and propidium iodide (PI) stains dead cells red. 
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Hypoxia
A number of ex-vivo culture conditions were tested 
to identify the optimal conditions that were used in this 
study. Initially 8% oxygen was used for CTC culture and 
CK+DAPI+ cells were observable at day 14, although the 
cells appeared to remain dormant until this time point. 
When the oxygen tension was brought down to 2%, 
these CK+DAPI+ cells were observable at day 7. The 
lower oxygen tension was preferred as this resulted in the 
proliferating cells at an earlier time point, which clinically 
meant a faster turnaround time. 
Table 3: Patient demographics
Variables N
Total 25 (100%)
Gender
 Male 20 (80%)
 Female 5 (20%)
Age, y
 < 60 10 (40%)
 > 60 15 (60%)
Anatomic site of primary
 Oral Cavity  6 (24%)
 Oropharyngeal 12 (48%)
 Supraglottis 3 (12%)
 Hypophayngeal 1 (4%)
 Larynx 1 (4%)
 Nasopharyngeal 2 (8%)
Tumour Size
 T1 0
 T2 0
 T3 8 (32%)
 T4 17 (68%)
Nodal spread
 N0 5 (20%)
 N1 2 (8%)
 N2a-c 18 (72%)
Distant metastases
 M0 25 (100%)
 M1 0
HPV status
 HPV-positive 7 (28%)
 HPV-negative 18 (72%)
CTC status
 CTC-positive 14 (Range from 1–15 CTCs/5 ml whole blood)
 CTC-negative 11
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Statistical analysis
The association between initial CTC counts 
and short term culture success was evaluated using 
the Mann-Whitney test. The association between the 
clinicopathological factors and short term culture success 
was evaluated using the Fisher’s exact test. P values less 
than 0.05 were considered statistically significant.
CONCLUSIONS
In this proof of principle study, we have shown that 
HNC patient derived CTCs can be cultured short term. 
Having said this, the underlying mechanisms involved 
such as co-infection with HPV need to be investigated. 
These findings need to be validated in larger cohorts of 
patients.
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